QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Sponsor
Fudan University
Study ID
NCT06786026
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • TNBC, Triple Negative Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    bevacizumab
  • QL1706 — DRUG
    Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
  • Nab paclitaxel — DRUG
    albumin-bound paclitaxel

Study Details

This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC

Key Dates

First listed
Jan 22, 2025
Start date
Oct 9, 2024
Status verified
Jan 2025
Primary completion
Sep 30, 2025
Completion
Dec 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: QL1706 +nab-P
  • Other: QL1706 +nab-P+bevacizumab.

Primary Outcome Measure

ORR by investigator [ Time Frame: At baseline, at the time point of every 6 weeks, up to 1 years ]

Central Contacts

Related Studies